Clearwater Analytics has received U.S. antitrust approval for acquisition of Enfusion, deal expected to close soon.

From NASDAQ.: 2025-02-26 21:10:25

Clearwater Analytics Holdings Inc. and Enfusion Inc. announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with Clearwater’s acquisition of Enfusion. The waiting period ended on February 24, 2025, satisfying a closing condition for the transaction. The deal, valued at $11.25 per share, is expected to close in the second quarter of 2025 pending Enfusion shareholder approval and other customary closing conditions. This acquisition includes $5.85 per share in cash and $5.40 per share in Clearwater Class A stock.



Read more at NASDAQ.: Clearwater Analytics – Enfusion Deal Receives U.S. Antitrust Approval